Proteasomes and proteasomal gene polymorphism in association with inflammation and various diseases

Medicina (Lithuania)

Volumn 49, Issue 5, 2013, Pages 207-213

  Žemeckiene, Živile ^a   Vitkauskiene, Astra ^a   Sjakste, Tatjana ^b   Šitkauskiene, Brigita ^a   Sakalauskas, Raimundas ^a  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^b UNIVERSITY OF LATVIA   (Latvia)

Author keywords

Inflammation; Proteasomal genes; Proteasome; Ubiquitin

Indexed keywords

EID: 84885797760     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.3390/medicina49050033     Document Type: Review

References (68)

1. Craiu A, Gaczynska M, Akopian T, Gramm CF, Fenteany G, Goldberg AL, et al. Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem 1997;272:13437-45.
2. Kim HM, Yu Y, Cheng Y. Structure characterization of the 26S proteasome. Biochim Biophys Acta 2011;1809:67-79.
3. Zhang D, Chen T, Ziv I, Rosenzweig R, Matiuhin Y, Bronner V, et al. Together, Rpn10 and Dsk2 can serve as a polyubiquitin chain-length sensor. Mol Cell 2009;36:1018-33.
4. Nandi D, Tahiliani P, Kumar A, Chandu D. The ubiquitinproteasome system. J Biosci 2006;31:137-55.
5. Dahlmann B. Role of proteasomes in disease. BMC Biochem 2007;8 Suppl 1:S3.
6. Nalepa G, Rolfe M, Harper JW. Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 2006;5:596-613.
7. Wang J, Maldonado MA. The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell Mol Immunol 2006;3:255-61.
8. Ciechanover A, Orian A, Schwartz AL. Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 2000;22:442-51.
9. Cook C, Petrucelli L. A critical evaluation of the ubiquitinproteasome system in Parkinson's disease. Biochim Biophys Acta 2009;1792:664-75.
10. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002;82:373-428.
11. Hartmann-Petersen R, Seeger M, Gordon C. Transferring substrates to the 26S proteasome. Trends Biochem Sci 2003;28:26-31.
12. Pickart CM. Ubiquitin in chains. Trends Biochem Sci 2000; 25:544-8.
13. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM. Recognition of the polyubiquitin proteolytic signal. EMBO J 2000;19:94-102.
14. Schwartz AL, Ciechanover A. Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu Rev Pharmacol Toxicol 2009;49:73-96.
15. von Mikecz A.The nuclear ubiquitin-proteasome system. J Cell Sci 2006;119(Pt 10):1977-84.
16. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003;29 Suppl 1:3-9.
17. Naujokat C, Hoffmann S. Role and function of the 26S proteasome in proliferation and apoptosis. Lab Invest 2002;82: 965-80.
18. Kisselev AF, Garcia-Calvo M, Overkleeft HS, Peterson E, Pennington MW, Ploegh HL, et al. The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J Biol Chem 2003;278:35869-77.
19. Ciechanover A. Intracellular protein degradation: from a vague idea through the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Neurodegener Dis 2012;10:7-22.
20. Kwak J, Workman JL, Lee D. The proteasome and its regulatory roles in gene expression. Biochim Biophys Acta 2011;1809:88-96.
21. Bhat KP, Greer SF. Proteolytic and non-proteolytic roles of ubiquitin and the ubiquitin proteasome system in transcriptional regulation. Biochim Biophys Acta 2011;1809:150-5.
22. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004;18:2195-224.
23. Janssen-Heininger YM, Poynter ME, Aesif SW, Pantano C, Ather JL, Reynaert NL, et al. Nuclear factor kappaB, airway epithelium, and asthma: avenues for redox control. Proc Am Thorac Soc 2009;6:249-55.
24. Liou HC. Regulation of the immune system by NF-kappaB and IkappaB. J Biochem Mol Biol 2002;35:537-46.
25. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107:135-42.
26. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280-8.
27. Karin M. The I?B kinase (IKK) complex as a critical regulator of immune responses. International Congress Series 2005;1285:97-103.
28. Lawrence T, Fong C. The resolution of inflammation: antiinflammatory roles for NF-kappaB. Int J Biochem Cell Biol 2010;42:519-23.
29. Wullaert A, Heyninck K, Janssens S, Beyaert R. Ubiquitin: tool and target for intracellular NF-kappaB inhibitors. Trends Immunol 2006;27:533-40.
30. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 2005;7:758-65.
31. Orian A, Gonen H, Bercovich B, Fajerman I, Eytan E, Israel A, et al. SCF(beta)(-TrCP) ubiquitin ligase-mediated processing of NF-kappaB p105 requires phosphorylation of its C-terminus by IkappaB kinase. EMBO J 2000;19:2580-91.
32. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell 2006; 22:245-57.
33. Elliott PJ, Zollner TM, Boehncke WH. Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med (Berl) 2003;81:235-45.
34. Moutzouris JP, Che W, Ramsay EE, Manetsch M, Alkhouri H, Bjorkman AM, et al. Proteasomal inhibition upregulates the endogenous MAPK deactivator MKP-1 in human airway smooth muscle: mechanism of action and effect on cytokine secretion. Biochim Biophys Acta 2010;1803:416-23.
35. Chauhan D, Anderson KC. Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas. BMC Biol 2011;9:72.
36. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS- 341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6.
37. Millward M, Price T, Townsend A, Sweeney C, Spencer A, Sukumaran S, et al. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs 2012;30:2303-17.
38. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012;120:947-59.
39. Shah IM, Lees KR, Pien CP, Elliott PJ. Early clinical experience with the novel proteasome inhibitor PS-519. Br J Clin Pharmacol 2002;54:269-76.
40. Elliott PJ, Ross JS. The proteasome: a new target for novel drug therapies. Am J Clin Pathol 2001;116:637-46.
41. Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol 2012;19:99-115.
42. Xie Y. Structure, assembly and homeostatic regulation of the 26S proteasome. J Mol Cell Biol 2010;2:308-17.
43. Sjakste T, Eglite J, Sochnevs A, Marga M, Pirags V, Collan Y, et al. Microsatellite genotyping of chromosome 14q13.2- 14q13 in the vicinity of proteasomal gene PSMA6 and association with Graves' disease in the Latvian population. Immunogenetics 2004;56:238-43.
44. Barbieri M, Marfella R, Rizzo MR, Boccardi V, Siniscalchi M, Schiattarella C, et al. The -8 UTR C/G polymorphism of PSMA6 gene is associated with susceptibility to myocardial infarction in type 2 diabetic patients. Atherosclerosis 2008;201:117-23.
45. Bennett DA, Xu P, Clarke R, Zondervan K, Parish S, Palmer A, et al. The exon 1-8C/G SNP in the PSMA6 gene contributes only a small amount to the burden of myocardial infarction in 6946 cases and 2720 controls from a United Kingdom population. Eur J Hum Genet 2008;16:480-6.
46. Liu X, Wang X, Shen Y, Wu L, Ruan X, Lindpaintner K, et al. The functional variant rs1048990 in PSMA6 is associated with susceptibility to myocardial infarction in a Chinese population. Atherosclerosis 2009;206:199-203.
47. Ozaki K, Sato H, Iida A, Mizuno H, Nakamura T, Miyamoto Y, et al. A functional SNP in PSMA6 confers risk of myocardial infarction in the Japanese population. Nat Genet 2006;38:921-5.
48. Heckman MG, Soto-Ortolaza AI, Diehl NN, Rayaprolu S, Brott TG, Wszolek ZK, et al. Genetic variants associated with myocardial infarction in the PSMA6 gene and Chr9p21 are also associated with ischaemic stroke. Eur J Neurol 2013;20(2):300-8.
49. Kalis M. Association study between (TG) repeat polymorphism in PSMA6 gene and type II diabetes mellitus in Botnia. Biologija 2003;2:12-4.
50. Sjakste T, Kalis M, Poudziunas I, Pirags V, Lazdins M, Groop L, et al. Association of microsatellite polymorphisms of the human 14q13.2 region with type 2 diabetes mellitus in Latvian and Finnish populations. Ann Hum Genet 2007; 71(Pt 6):772-6.
51. Sjakste T, Poudziunas I, Ninio E, Perret C, Pirags V, Nicaud V, et al. SNPs of PSMA6 gene - investigation of possible association with myocardial infarction and type 2 diabetes mellitus. Genetika 2007;43:553-9.
52. Alsmadi O, Muiya P, Khalak H, Al-Saud H, Meyer BF, Al- Mohanna F, et al. Haplotypes encompassing the KIAA0391 and PSMA6 gene cluster confer a genetic link for myocardial infarction and coronary artery disease. Ann Hum Genet 2009;73(Pt 5):475-83.
53. Trapina I, Rumba-Rozenfelde I, Sjakste N, Sokolovska J, Sugoka O, Sjakste T. Association study of genetic variants in the 14q11-14q13 Proteasomal genes cluster with juvenile idiopathic arthritis (JIA) in Latvian population. Proceedings of the Latvian Academy of Sciences Section B Natural Exact and Applied Sciences. 2009;63:214-21.
54. Sjakste T, Trapina I, Rumba-Rozenfelde I, Lunin R, Sugoka O, Sjakste N. Identification of a novel candidate locus for juvenile idiopathic arthritis at 14q13.2 in the Latvian population by association analysis with microsatellite markers. DNA Cell Biol 2010;29:543-51.
55. Wong ML, Dong C, Maestre-Mesa J, Licinio J. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol Psychiatry 2008;13:800-12.
56. Deng GY, Muir A, Maclaren NK, She JX. Association of LMP2 and LMP7 genes within the major histocompatibility complex with insulin-dependent diabetes mellitus: population and family studies. Am J Hum Genet 1995;56:528-34.
57. Camarena A, Aquino-Galvez A, Falfan-Valencia R, Sanchez G, Montano M, Ramos C, et al. PSMB8 (LMP7) but not PSMB9 (LMP2) gene polymorphisms are associated to pigeon breeder's hypersensitivity pneumonitis. Respir Med 2010;104:889-94.
58. Banerjee I, Gupta V, Ahmed T, Faizaan M, Agarwal P, Ganesh S. Inflammatory system gene polymorphism and the risk of stroke: a case-control study in an Indian population. Brain Res Bull 2008;75:158-65.
59. Ikeda S, Tanaka N, Arai T, Chida K, Muramatsu M, Sawabe M. Polymorphisms of LTA, LGALS2, and PSMA6 genes and coronary atherosclerosis: a pathological study of 1503 consecutive autopsy cases. Atherosclerosis 2012;221:458-60.
60. Wang H, Jiang M, Zhu H, Chen Q, Gong P, Lin J, et al. Quantitative assessment of the influence of PSMA6 variant (rs1048990) on coronary artery disease risk. Mol Biol Rep 2013;40:1035-41.
61. Amos CI, Gorlov IP, Dong Q, Wu X, Zhang H, Lu EY, et al. Nicotinic acetylcholine receptor region on chromosome 15q25 and lung cancer risk among African Americans: a case-control study. J Natl Cancer Inst 2010;102:1199-205.
62. Hansen HM, Xiao Y, Rice T, Bracci PM, Wrensch MR, Sison JD, et al. Fine mapping of chromosome 15q25.1 lung cancer susceptibility in African-Americans. Hum Mol Genet 2010;19:3652-61.
63. Liu P, Vikis HG, Wang D, Lu Y, Wang Y, Schwartz AG, et al. Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Cancer Ins 2008;100: 1326-30.
64. Liu Y, Liu P, Wen W, James MA, Wang Y, Bailey-Wilson JE, et al. Haplotype and cell proliferation analyses of candidate lung cancer susceptibility genes on chromosome 15q24-25.1. Cancer Re 2009;69:7844-50.
65. Bachmann HS, Novotny J, Sixt S, Liebisch P, Frey UH, Duhrsen U, et al. The G-allele of the PSMA6-8C>G polymorphism is associated with poor outcome in multiple myeloma independently of circulating proteasome serum levels. Eur J Haematol 2010;85:108-13.
66. Arima K, Kinoshita A, Mishima H, Kanazawa N, Kaneko T, Mizushima T, et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci U S A 2011;108:14914-9.
67. Sharma P, Halayko AJ. Emerging molecular targets for the treatment of asthma. Indian J Biochem Biophys 2009;46: 447-60.
68. Elliott PJ, Pien CS, McCormack TA, Chapman ID, Adams J. Proteasome inhibition: a novel mechanism to combat asthma. J Allergy Clin Immunol 1999;104(2 Pt 1):294-300.